Subconjunctival Bevacizumab and Recurrent Pterygium

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto de Olhos de Goiania
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Recurrent pterygium

Exclusion Criteria:

• Pregnant or lactating women

• History of myocardial infarction

• History of stroke